Revolutionizing disease treatment through bioengineered probiotics and glucagon‐like peptide 1 (GLP‐1) based strategies: A path towards effective cures

Autor: Smriti Jain, Adarsh Kumar Shukla, Deepika, Surbhi Panwar, Anita Kumari, Ashok Kumar Yadav, Ashwani Kumar

Publikováno v: Food Bioengineering, Vol 3, Iss 3, Pp 280-300 (2024)

Abstract Human intestinal gut microbiota harbors complex and diverse microbes that play an important role in maintaining the homeostasis of the intestinal microenvironment in humans. The rise in mortality and morbidity rates among humans because of t

Externí odkaz: https://doaj.org/article/78e9ee3989ac4a2e89ac89c6eaa02510

Urinary Proteome Differences in Patients with Type 2 Diabetes Pre and Post Liraglutide Treatment

Autor: Mohamed Rafiullah, Hicham Benabdelkamel, Afshan Masood, Aishah A. Ekhzaimy, Mohthash Musambil, Salini Scaria Joy, Assim A. Alfadda

Publikováno v: Current Issues in Molecular Biology, Vol 45, Iss 2, Pp 1407-1421 (2023)

Diabetes mellitus is a chronic multisystem disease with a high global prevalence. The glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide is known to lower glucose levels and reduce weight. However, the mechanisms underlying the benefits of

Externí odkaz: https://doaj.org/article/f3eb8dcc9c35436cab0a607e6c7ed7e3

How glucagon-like peptide 1 receptor agonists work

Autor: Andreas Breenfeldt Andersen, Christine Rode Andreasen, Tina Vilsbøll, Filip K. Knop

Publikováno v: Andreasen, C R, Andersen, A, Knop, F K & Vilsbøll, T 2021, ' How glucagon-like peptide 1 receptor agonists work ', Endocrine Connections, vol. 10, no. 7, pp. R200-R212 . https://doi.org/10.1530/EC-21-0130
Endocrine Connections, Vol 10, Iss 7, Pp R200-R212 (2021)
Endocrine Connections

In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ba1d8d324fd6540c0fe41f0cc42cbe5
https://curis.ku.dk/ws/files/275530666/_20493614_Endocrine_Connections_How_glucagon_like_peptide_1_receptor_agonists_work.pdf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Cracking the combination: Gut hormones for the treatment of obesity and diabetes

Autor: Tricia Tan, Oluwaseun Anyiam, Kleopatra Alexiadou

Publikováno v: Journal of Neuroendocrinology
e12664

Obesity and type 2 diabetes are a veritable global pandemic. There is an imperative to develop new therapies for these conditions that can be delivered at scale to patients, which deliver effective and titratable weight loss, amelioration of diabetes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::174b51ae180a0c0abb580ea079d2dc11
http://europepmc.org/articles/PMC6563152